PF-06305591

• Description :

  PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Sodium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/PF-06305591.html

• Purity :

  99.74

• Solubility :

  DMSO : 140 mg/mL (ultrasonic)

• Smiles :

  CC(C)(C)C1=CC=C(NC([C@H]([C@@H](C)C(N)=O)N)=N2)C2=C1

• Molecular Formula :

  C15H22N4O

• Molecular Weight :

  274.37

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Brown AD, et al. The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain. Bioorg Med Chem. 2019 Jan 1;27 (1) :230-239.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  Nav1.8

• CAS Number :

  [1449473-97-5]